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Is cancer progression caused by gradual
or simultaneous acquisitions of new
chromosomes?
Mathew Bloomfield1,2 and Peter Duesberg1*
Abstract
Background: Foulds defined, “Tumor progression (as a) permanent, irreversible qualitative change in one or more
of its characters” (Cancer Res. 1954). Accordingly progressions, such as metastases and acquired drug-resistance,
were since found to be subspecies of cancers with conserved and numerous new chromosomes. Here we ask
whether cancers acquire numerous new chromosomes gradually or simultaneously in progressions. The currently
prevailing theory of Nowell (Science, 1976) holds that unexplained “genetic instability” generates “variant sublines
(with) changes in chromosome number” and that “clonal” progressions arise by “stepwise selection of more
aggressive sublines”. The literature, however, contains many examples of “immediate” selections of progressions
with numerous new chromosomes - notably experimentally initiated fusions between cancers and heterologous
cells. Furthermore, the stepwise progression theory predicts intermediate sublines of cancers with multiple
non-clonal additions of new chromosomes. However, the literature does not describe such intermediates.
Results: In view of these inconsistencies with stepwise progression we test here a saltational theory, in which
the inherent variability of cancer-specific aneuploidy generates “immediate” progressions with individual clonal
karyotypes, transcriptomes and phenotypes in single steps. Using cell fusion as an established controllable model of
“immediate” progression, we generated seven immortal murine hybridomas by fusing immortal murine myeloma
cells and normal antibody-producing B-cells with polyethylene glycol within a few minutes. These immortal
hybridomas contained individual sets of 71 to 105 clonal chromosomes, compared to the 52 chromosomes of the
parental myeloma. Thus the myeloma had gained 19 to 53 new clonal chromosomes in seven individual
hybridomas in a single step. Furthermore, no stable intermediates were found, as would be predicted by a
saltational process.
Conclusions: We conclude that random fusions between myelomas and normal B-cells generate clonal hybridomas
with multiple, individual chromosomes in single steps. Similar single-step mechanisms may also generate the “late”
clonal progressions of cancers with gains of numerous new chromosomes and thus explain the absence of
intermediates. Latency would reflect the low probability of rare stochastic progressions. In conclusion, the karyotypic
clonality of hybridomas and spontaneous progressions suggests karyotypic alterations as proximate causes of
neoplastic progressions. Since cancer-specific aneuploidy catalyzes karyotypic variation, the degree of aneuploidy
predicts the clinical risk of neoplastic progression, confirming classical predictions based on DNA content.
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Background
Foulds defined, “Tumor progression (as a) permanent,
irreversible qualitative change in one or more of its char-
acters” [1]. Accordingly several labs including ours have
recently shown that progressions such as metastases and
drug-resistant variants are actually clonal subspecies of
cancers with parental and typically numerous new chro-
mosomes [2–13].
Here we ask whether multiple new chromosomes of
progressions are acquired gradually or simultaneously in
one-off events.
The currently prevailing theory of Nowell (Science,
1976) holds that unexplained “genetic instability” gener-
ates “variant sublines (with) changes in chromosome
number” and that “clonal” progressions arise by “step-
wise selection of more aggressive sublines” [14]. The lit-
erature, however, contains numerous examples of
selections of “immediate” progressions [14] with mul-
tiple new chromosomes [7, 15–18] - notably experimen-
tally initiated fusions between cancers and heterologous
cells [18–26]. Furthermore, the prevailing stepwise the-
ory predicts stable intermediate sublines of cancers with
multiple non-clonal additions of new chromosomes.
However, the literature does not support the existence of
non-clonal intermediates [14, 26, 27].
Alternative single-step theory of progression
In view of these inconsistencies with stepwise progres-
sion we test here a single-step or saltational theory of
progression, in which the inherent instability of cancer-
specific aneuploidy catalyzes steady karyotypic variations
in single steps automatically by unbalancing thousands
of balance-sensitive genes. Most of these variants alter
parental cancer karyotypes within clonal margins of
cancer-specific autonomy, typically by the gain or loss of
single copies of chromosomes, while others lose auton-
omy and thus perish [9, 28–31].
A small minority of these random karyotypic variations
would however, acquire new autonomous clonal karyo-
types, transcriptomes and phenotypes, which are still re-
lated to, but distinct from parental predecessors [9–13,
32]. These new subspecies or progressions are also clon-
ally stabilized by selections for cancer-specific autonomy,
just like parental cancers are [9–12, 28, 29, 33, 34].
Using cell fusion as an established controllable model of
“immediate” progression, we generated seven individual
murine hybridomas of immortal murine myeloma cells
and normal antibody-producing B-cells by fusing these
cells with polyethylene glycol in a virtually immediate fu-
sion process of minutes [21, 23, 25, 35]. Such progressions
would thus be new clonal subspecies of parental cancers.
A saltational mechanism of progression would make three
testable predictions: (1) Time-independent progressions
with unpredictable numbers of chromosomes at low
stochastic rates – just like de novo carcinogenesis [9]. (2) As
per definition the saltational mechanism would also predict
the absence of stable intermediates [9, 11, 30]. (3) The the-
ory would also predict spontaneous progressions of progres-
sions on the same principles as primary progressions.
In an effort to distinguish between a single step and
multi-step theories, we tested an established experimental
system of “immediate” progression [14], namely the
immortalization of antibody-producing murine B-cells by
fusion (or cell hybridization) with immortal murine mye-
loma cells to “hybridomas” [21, 23, 35] (Fig. 1). In this
system, fusions of immortal myeloma cells convert normal
B-cells to immortal clonal hybridomas in a few minutes in
the presence of inactivated Sendai virus or polyethylene
glycol- at rates of 10^-4 to 10^-5 hybridoma per myelolma
cells [23, 35–37]. This short reaction time effectively limits
fusion events to a single step process [21, 23, 35]. The
resulting hybridoma clones are indeed already known to
have new hybrid karyotypes [23, 26, 38] (Fig. 1). To test
the predictions of our theory that simultaneous acquisi-
tions of multiple new chromosomes may generate clonal
progressions or subspecies in single steps, we prepared
and analyzed the chromosomes and phenotypes of seven
new immortal hybridomas.
In short we found that all seven hybridomas were
individual subspecies of the parental myeloma with
numerous new clonal chromosomes and that there were
no karyotypic intermediates. These results support a salta-
tional process of cancer progression.
Results
In the following we describe: (a) The preparation of seven
hybridomas as models of immediate saltational progres-
sions by experimental fusions of immortal murine mye-
loma Ag8 cells and normal B-cells (Fig. 1 and Methods).
(b) Evidence for individual phenotypes of these hybrid-
omas, which the saltational theory postulates based on se-
lection of random recombinations of chromosomes of two
or more cells hybridized by fusion. (c) Evidence for the
clonality and individuality of the karyotypes of hybridomas,
which the saltational theory postulates based on the low
probability that random fusions of chromosomes of two
types of cells generate a new immortal hybridoma species.
Preparation of hybridomas
Our colleagues Jennifer Zeitler and Robert Beatty kindly
offered to us seven hybridomas from their undergradu-
ate course in immunology here at UC Berkeley. Follow-
ing published procedures, these hybridomas were
prepared by fusions of immortal mouse myeloma Ag8
cells without functional thymidine kinase genes with
equal amounts of normal thymidine kinase-positive B-
cells and selections for immortal thymidine-dependent
hybridoma clones in the presence of aminopterin, an
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inhibitor of de novo thymidine synthesis [21, 23, 26, 35,
36] (Fig. 1, Methods). Based on these procedures our mye-
loma and B-cells were fused with polyethylene glycol for
several minutes, then washed and incubated in selective
medium containing aminopterin and thymidine. As
shown graphically in Fig. 1, under these conditions only
cell hybrids between myeloma-specific immortalizing
chromosomes (defined below) and B-cell-derived thymi-
dine kinase-positive chromosomes survive. By contrast
un-fused myeloma cells perish, because de novo DNA
synthesis is inhibited by aminopterin or because cells are
damaged by polyethylene glycol [35, 38]. At the same time
un-fused B-cells perish spontaneously in cell culture in a
few cell generations.
As described previously, only about one in 10^4 – 5
myeloma Ag8 cells is converted to an immortal hybrid-
oma cell by fusion with equal amounts of B-cells under
these conditions [23, 35–37]. These low yields of pro-
gressions or subspeciation from myeloma to hybridoma
are consistent with the low probabilities to generate new
autonomous subspecies by random variation of the
chromosomes of an existing species [9–11, 28, 33, 34]
(Background).
Within one to two weeks after fusion we first detected
hybridoma clones emerging in this selective medium as
microscopic clones. Seven of such hybridoma clones
were then grown to about 10^6 cells for karyotypic and
phenotypic analyzes, typically about a month after fusion
or later [23, 26, 36].
As shown in Table 1, three of these seven hybridomas
were confirmed to produce antibodies against the spe-
cific antigens used to immunize the mice from which
the B-cells derived by our colleagues Zeitler and Beatty,
and hence termed Hyb CN-13 ab+, Hyb cl-12 ab + and
Hyb cl-9 ab+. Table 1 also lists the remaining four hy-
bridomas that were not tested for the production of anti-
bodies against inducing antigens and thus labeled Hyb
H12 ab-, Hyb F3 ab-, and Hyb 94 and Hyb 1-5 for rea-
sons described below.
Clonal phenotypes of hybridomas
To test our theory that hybridomas are individual,
clonal subspecies of myelomas with individual pheno-
types [10, 11], we first looked at cell morphologies. As
shown in Fig. 2a-c the cells of the myeloma Ag8 and of
the two hybridomas Hyb H12 ab- and Hyb CN-13 ab +
were spherical, like all other hybridomas (not shown)
and thus hard to distinguish from each other morpho-
logically - in contrast to the distinct 2-dimensional
morphologies of cells from solid cancers attached to
culture dishes as described by us elsewhere [11]. Never-
theless, both myeloma Ag8 and hybridoma Hyb H12
ab- differed from Hyb CN-13 ab + in forming 3-
dimensional aggregates of cells in suspension, in which
1) Immortalizing myeloma 
chromosomes 
2) tk+ mouse chromosome 
3) Individual combinations 
of mouse and myeloma 
chromosomes
1. Immortalizing myeloma 
chromosomes (red)
2. tk-deficient







Chromosome complexes with either
1) defective cell membranes  
2) or non-immortalizing 
chromosome complexes 
3) or no tk-positive chromosome 
Fig. 1 Generation of mouse hybridomas by fusions of immortal thymidine kinase(tk)-less mouse myeloma cells with normal mouse B-cells in about
50% polyethylene glycol [26, 35, 36]. After fusions of 5 to 10 min immortal myeloma-B-cell hybrids or hybridomas survive in the presence of the inhibi-
tor of DNA synthesis aminopterin on supplemental thymidine picked up by B-cell-derived kinase. The majority of fused cells die from defective cell
walls randomly denatured by polyethylene glycol or from non-proliferative chromosome combinations without myeloma-specific immortalizing chro-
mosomes and or from lack of chromosomes with B-cell specific kinase
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they are attached to each other. The non-attached cells
settled at the bottom of the dish. In contrast all Hyb
CN-13 ab + cells formed a dense layer of loose cells at
the bottom of the dish. In addition Hyb CN-13 ab +
cells were on average a bit larger than Hyb H12 ab- and
myeloma cells.
Furthermore, Table 1 shows that some hybridomas dif-
fered from others in the production of specific antibodies,
e.g. Hyb CN-13 ab+, Hyb cl-12 ab+, Hyb cl-9 ab+. By con-
trast, Hyb H12 ab- and Hyb F3 ab- are probably antibody-
negative, although they were not directly tested, for two
reasons: 1) As shown below in Fig. 6, they both lacked in-
tact copies of murine chromosome 12, which encodes the
heavy chain of mouse antibodies [39], and 2) The parental
myeloma Ag8 of the hybridomas studied here also lacks
functional antibody genes [40]. It would follow that both
of these clones are antibody-negative.
Moreover the seven hybridomas could be distinguished
by individual growth rates (data not shown). For example,
hybridomas Hyb H12 ab-, Hyb F3 ab- and Hyb 94 grew
about twice as fast as the three anti-body-producing
hybridomas Hyb CN-13 ab+, Hyb cl-12 ab+, Hyb cl-9 ab
+ and the hybridoma Hyb 1-5 (Table 1). These individual-
ities of our hybridomas confirmed and extended earlier
observations by Kohler and Milstein [23].
In sum, we conclude that the seven hybridomas have
descriptively and functionally distinct clonal phenotypes.
Next we set out to determine whether the chromo-
somes of our hybridomas were indeed individual and
clonal as predicted by the saltational theory.
Are the chromosomes of hybridomas individual and
clonal as predicted by the saltational theory?
The saltational theory of the origin of progressions pre-
dicts that each progression of a clonal cancer is a new,
individual sub-clone with clonal parental and new
progression-specific chromosomes. To test this predic-
tion of the saltational theory of progression, we asked
whether the seven hybridomas each contained individual
sets of clonal chromosomes.
To answer this question chromosome numbers of in-
dividual hybridoma cells were determined from karyo-
types prepared from metaphase chromosomes. Owing to
the inherent clonal heterogeneity of the chromosome
numbers of cancer karyotypes, generated by cancer-
specific aneuploidy (see Background, Alternative single-
step theory of progression), we used averages of the pri-
mary chromosome numbers of five individual cells as
standards of clonality.
Examples of individual karyotypes of three hybridomas,
namely hybridomas Hyb CN-13 ab+, Hyb H12 ab- and
Hyb F3 ab-, and of the parental myeloma Ag8 are shown
in Fig. 3a-d. As can be seen in this figure, each immortal
hybridoma contained individual chromosome numbers, as
predicted by the theory that hybridomas are individual
subspecies of the myeloma. Moreover the individual num-
bers of chromosomes of these karyotypes already indi-
cated that each hybridoma apparently contained
considerably more chromosomes than the parental mye-
loma, although clonality had yet to be determined.
To determine clonality the chromosome numbers, five
individual cells of each hybridoma and parental myeloma
were compared in 3-dimensional tables, termed ‘karyo-
type arrays’ [11]. Such arrays list the numbers of all
intact and marker chromosomes on the x-axis, the copy
numbers of the chromosomes on the y-axis, and the
numbers of karyotypes (K) analyzed on the z-axis. The
resulting 3-dimensional arrays show clonality as parallel
lines, which are formed by chromosomes from distinct
cells with the same copy numbers. At the same time,
non-clonal chromosomes show up as readily detectable
non-parallel lines in karyotype arrays.
In the following we show the karyotype arrays of our
seven hybridomas and of the parental myeloma in pair-
wise comparisons in Figs. 4, 5, 6 and 7 and the resulting
average clonal chromosome numbers in Table 1 and pri-
mary numbers in Tables 2 and 3:





Gains of chromosomes compared
to the 52 of myeloma
Gains / losses of chromosomes compared to
the 92 of a theoretical myeloma-B-cell hybrid
Mouse 40 – –
Myeloma Ag8 52 ± 1 – –
Hyb CN-13 ab+ 85 ± 2 33 - 7
Hyb cl-12 ab+ 86 ± 9 34 - 6
Hyb cl-9 ab+ 105 ± 11 53 + 13
Hyb H12 ab- 71 ± 2.5 19 - 21
Hyb F3 ab- 79 ± 2 27 - 13
Hyb 94 74 ± 5 22 - 18
Hyb 1-5 99 ± 7.5 47 + 7
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Karyotype-arrays of myeloma Ag8 and hybridoma Hyb
CN-13 ab + (Fig. 4a, b). As can be seen in Fig. 4a and in
Tables 1 and 2 most chromosomes of five karyotypes of
myeloma Ag8 arrayed in panel (a) and of hybridoma
CN-13 ab + arrayed in panel (b) formed parallel lines
and are thus clonal. The resulting percentages of clonal-
ities are listed on the x-axis of the arrays, above the
respective chromosome numbers. With few exceptions
they were predominantly 80 to 100% clonal. At the same
time minorities of some chromosomes were non-clonal,
differing from the majority of clonal counterparts mostly
in the gains or losses of single chromosomes as shown
in Fig. 4 and listed in Table 2.
Moreover the comparison of the two arrays shows the
individualities of the two clones, and also their similarities.
These similarities consisted primarily of 31 highly clonal
and highly abnormal marker chromosomes shared by
myeloma Ag8 and hybridoma CN-13 ab+. Further, the
myeloma lacked several normal mouse chromosomes and
shared all of its normal murine chromosomes with the hy-
bridoma CN-13 ab+, although at lower copy numbers
than in the hybridoma. The individualities and commonal-
ities of the two karyotype-arrays thus confirmed the pre-
liminary results of the single karyotypes of these clones
shown above in Fig. 3a, b., namely that the myeloma had
gained 33 new clonal chromosomes in its conversion to
hybridoma CN-13 ab + (Table 1). The relatively high nu-
merical gain of chromosomes by the hybridoma compared
to the parental myeloma in the short times of fusion thus
supports the single-step theory of progression.
Karyotype-arrays of hybridomas Hyb cl-12 ab + and
Hyb cl-9 ab + (Fig. 5a, b). As can be seen in Fig. 5 (and
Table 2), the copy numbers of most chromosomes of the
karyotypes of Hyb cl-12 ab + and of Hyb cl-9 ab +
formed parallel lines and are thus quasi-clonal. The pre-
vailing 60 to 100% clonalities of the chromosomes are
listed on the x-axis of the arrays, above the respective
chromosome numbers. At the same time the copy num-
ber of the remaining non-clonal minorities of certain
chromosomes typically differed from the majority of
clonal counterparts mostly in the gains or losses of sin-
gle chromosomes as shown in Fig. 5 and in Table 2.
Moreover comparison of the two arrays shows the in-
dividualities of the two clones and also their similarities.
These similarities consisted again primarily of the 31
highly clonal, myeloma-specific marker chromosomes,
which are also shared with the hybridoma shown in
Fig. 4. This is further correlative evidence that the 31
myeloma-specific marker chromosomes encode the
common, myeloma-specific immortality [30].
Further, the two hybridomas Hyb cl-12 ab + and Hyb
cl-9 ab + shared with each other and with hybridoma
CN-13 ab + all normal murine chromosomes, but mostly
at hyper-diploid copy numbers. This suggests that prob-
ably more than one mouse B-cells were fused with the
myeloma parent in the formation of these hybridomas.
With regard to the mechanism of progression, we
emphasize again that the average clonal chromosome
copy number of hybridoma cl-12ab + was 86 and that of
hybridoma cl-9 ab + was 105. These hybridomas thus
differ from the parental myeloma in 34 and 53 additional
1
a Myeloma Ag8
b Hybridoma 12 ab-
c Hybridoma CN-13 ab+
Fig. 2 a, b, c Cell morphology of murine myeloma Ag8 (a),
hybridoma Hyb H12 ab- (b) and hybridoma Hyb CN-13 ab + (c) with
phase contrast microscopy at 200× magnification in cell culture. The
cells are growing in suspension in medium RPMI 1640 (Methods).
Under these conditions Ag8 myeloma and hybridoma Hyb H12
ab- cells form clumps of loosely attached cells, while all hybridoma
Hyb CN-13 ab + are settled on the bottom of the culture dish
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chromosomes respectively (Tables 1 and 2). These rela-
tively high numerical gains of chromosomes by the hy-
bridomas compared to the parental myeloma in the
short times of fusions again support the single-step the-
ory of progression.
Karyotype-arrays of hybridomas Hyb H12 ab- and Hyb
F3 ab- (Fig. 6a, b). As can be seen in Fig. 6, the copy
numbers of most chromosomes of the karyotypes of hy-
bridomas Hyb H12 ab- and Hyb F3 ab- formed parallel
lines. The exact percentages of the clonalities of the
chromosomes ranged between 60 to 100% as listed on
the x-axis of the arrays above the respective chromo-
some numbers. The corresponding chromosomes are
thus quasi-clonal. At the same time the copy number of
non-clonal minorities of these chromosomes typically
differed from the majority of clonal counterparts mostly
in the gains or losses of single chromosomes, as shown
in Fig. 6 and listed in Table 3.
Moreover comparison of the two arrays shows the
individualities of the two clones and also their simi-
larities. Again these similarities consisted primarily of
the 31 highly clonal, myeloma-specific marker chro-
mosomes, which are also shared with the three
hybridomas shown in Figs. 4 and 5 (and those shown
in Fig. 7 below). This confirms again the view that
the 31 myeloma-specific marker chromosomes encode
the common, myeloma-specific neoplastic immortality
[30]. Further, the two antibody-negative (ab-) hybridomas
H12 ab- and F3 ab- both lacked mouse chromosome 12.
Notably chromosome 12 is also missing in the parental
myeloma (Fig. 4a) and is known to encode the heavy chain
of moues antibodies [36, 39, 40]. In view of this, we
pointed out above that the absence of intact chromosome
12 in Hyb H12 ab- and Hyb F3 ab- and the lack of func-
tional antibody in the parental myeloma Ag8 indicate that
these two hybridomas must both be antibody-negative
(see Results, Clonal phenotypes of hybridoma). As ex-
pected, the individual and common chromosomes of Hyb
H12 ab- and Hyb F3 ab- shown above in the karyotypes of
Fig. 3c, d. confirmed and extended the patterns of the two
arrays shown here, namely that hybridomas contained nu-
merous new chromosomes compared to the parental
myeloma.
With regard to the mechanism of progression, we
emphasize again that the numbers of clonal chromo-
somes of the hybridoma H12 ab- are 71 and those of F3
ab- are 79 (Tables 1 and 3) and are thus significantly
higher than the 52 chromosomes of the parental
myeloma Ag8. They differed from the parental myeloma
in 19 and 27 additional, clonal chromosomes (Tables 1
and 3). These relatively high numerical gains of chromo-
somes by the hybridomas compared to the parental mye-
loma in the short times of fusions thus support again
the single-step theory of progression.
Mouse Myeloma Ag8 Hybridoma CN -13 ab+




Fig. 3 a, b, c, d Karyotypes of murine myeloma Ag8 (a), and three hybridoma subspecies of myeloma Ag8, Hyb CN-13 ab + (b), Hyb H12 ab-
(c) and Hyb F ab- (d). It can be seen that all four immortal clones shared the myeloma-specific set of about 31 marker chromosomes, which
define the karyotype of the immortal myeloma clone, from which the hybridomas were derived
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Karyotype-arrays of hybridomas Hyb 94 and Hyb 1-5
(Fig. 7a, b). As can be seen in Fig. 7a (and Table 3) the
individual chromosome numbers of the five hybridoma
Hyb 94 cells analyzed formed several non-parallel lines
and accordingly ranged from 71 to 82 chromosomes per
cell - for a clonal average of 74 (Table 1). This hybrid-
oma is thus clonally heterogeneous. Nevertheless, all five
Hyb 94 karyotypes shared two Hyb 94-specific marker
chromosomes and all but three of the 31 myeloma-
specific chromosomes (Table 3). The Hyb 94 karyotypes
are thus quasi-clonal, with copy numbers ranging from
40 to 100% clonality (Fig. 7a). The simplest explanation
for the relatively high clonal heterogeneity of Hyb 94
suggests that this clone is a sub-clonal precursor of a
a
b
Fig. 4 a, b Karyotype-arrays of mouse myeloma Ag8 (a) and the corresponding hybridoma subspecies Hyb CN-13 ab + (b). Karyotype-arrays
compare the copy numbers of individual chromosomes of multiple karyotypes of a potential cell clone in three-dimensional tables. The tables list
the chromosome numbers of arrayed karyotypes, K1 to K5, on the x-axis, the copy numbers of each chromosome on the y-axis, and the number
of the five karyotypes arrayed on the z-axis, as described by us [9, 11] and others [12]. Since chromosomes with the same copy numbers form
parallel lines in 3-dimensonal karyotype arrays they visually identify clonality. The clonality of each chromosome in percent is listed on the ab-
scissa of each array. Here we compared the karyotype array of myeloma Ag8 (a) to that of an antibody-producing (ab+) hybridoma subspecies
Hyb CN-13 ab + (b). As can be seen in Fig. 4 and Table 2, hybridoma Hyb CN-13 ab + shared with the parental myeloma about 31 highly clonal,
myeloma-specific marker chromosomes. In addition the hybridoma shared with the parental myeloma clonal copies of all myeloma-specific
normal mouse chromosomes, although the copy numbers of shared mouse chromosomes were 2-3-fold higher in the hybridoma than in the
myeloma. By contrast the myeloma lacked several normal mouse chromosomes. Based on the shared clonal myeloma-specific marker and normal
mouse chromosomes, the hybridoma Hyb CN-13 ab + is a subspecies of the myeloma and the murine B-cell. It is consistent with the complete
set of normal mouse B-cell chromosomes of this hybridoma that it produced antibodies
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hybridoma that is losing non-clonogenic chromosomes
after it originated from a fusion of myeloma with B-cells.
Such clonal heterogeneity has also been observed previ-
ously in metastases of solid cancers [11].
As shown in Fig. 7b, the karyotype array of Hyb 1-5 was
also relatively heterogeneous. The clonality of chromo-
some numbers ranged from 40 to 100% and averaged at
about 60% (Fig. 7b). Nevertheless, all five Hyb 1-5 karyo-
types shared all but one of the 31 myeloma-specific chro-
mosomes (Table 3). The simplest explanation for the high
clonal heterogeneity of Hyb 1-5 suggests again that this
clone, like Hyb 94 above, is a heterogeneous precursor of a
prospective hybridoma that is losing non-clonogenic chro-
mosomes after it originated from an unstable fusion of
myeloma with B-cells.
With regard to the mechanism of progression, we
emphasize again that the average numbers of quasi-clonal
chromosomes of hybridoma Hyb 94, namely 74, and of Hyb
1-5, namely 99, differed from the parental set of myeloma
chromosomes by 22 and 47 additional chromosomes
a
b
Fig. 5 a, b Karyotype-arrays of five cells (K1 to K5) of hybridoma Hyb cl-12 ab + (a) and hybridoma Hyb cl-9 ab + (b). As described in Fig. 4
karyotype-arrays reveal the clonality of cancer-specific chromosomes based on the percentage of cells with chromosomes that form parallel lines
and thus have identical copy numbers. The arrays of hybridoma Hyb CN-13 ab + and of hybridoma Hyb cl-9 ab + shared highly clonal copies of
all 31 myeloma-specific, abnormal marker chromosomes described in Fig. 4a and Table 2. They also share highly clonal copies of all normal
mouse chromosomes from the parental B-cell, although at individually distinct copy numbers. Based on the shared clonal myeloma-specific and
clonal normal mouse chromosomes shown in Table 2, the two hybridomas are individually distinct clonal subspecies of the myeloma and normal
B-cell. The presence of complete sets of normal mouse chromosomes in both hybridomas is consistent with their production of
mouse anti-bodies
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respectively (Table 1). This multiplicity of newly acquired
chromosomes during the short fusion events again supports
a single step model of fusion-mediated neoplastic progres-
sion, which continued to evolve after fusion.
Discussion
Multiple studies including ours have found “late” but also
“immediate” progressions of cancers with numerous new,
progression-specific chromosomes [14, 25, 41]. However
no intermediates or prospective progressions with subsets
of new progression-specific chromosomes were reported.
In view of this and the existence of “immediate”
progressions with numerous new chromosomes we have
advanced here the theory that neoplastic progressions are
saltational events, in which all chromosomes of progres-
sions are united in single steps. To test this saltational
theory, we asked here, whether the numerous new chro-
mosomes of most neoplastic progressions are acquired
gradually or simultaneously in single steps.
Simultaneous acquisitions of numerous new chromosomes
convert myelomas to immortal hybridomas in single steps
In view of evidence that neoplastic progressions of certain
cancers, notably immortal hybridomas from myelomas
a
b
Fig. 6 a, b Karyotype-arrays of five cells of hybridoma Hyb 12 ab- (a) and hybridoma Hyb F3 ab- (b). The arrays of hybridoma Hyb 12 ab- and of hy-
bridoma Hyb F3 ab- shared highly clonal copies of the 31 myeloma-specific marker chromosomes described in Fig. 4. They also shared highly clonal
copies of all normal mouse chromosomes from the parental B-cell, although at individually distinct copy numbers. Based on the shared clonal
myeloma-specific and normal mouse chromosomes (see Table 3), the two hybridomas are individually distinct, clonal subspecies of the myeloma and
normal B-cells. The absence of normal mouse chromosome 12, which encodes the heavy chain of mouse antibodies in both hybridomas explains their
failure to produce of mouse antibodies (see text, Are the chromosomes of hybridomas individual and clonal as predicted by the saltational theory?)
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can be generated within a few minutes by fusions of heter-
ologous cells, we tested our saltational theory by analyses
of the chromosomes of seven hybridomas for new hybrid-
oma-specific chromosomes and for the absence of detect-
able intermediates.
As shown in Table 1, our experiments demonstrated
that seven individual and immortal hybridomas had in-
deed gained from 19 to 53 chromosomes from fusions
with B-cells within a few minutes – and that there were
no detectable intermediates. We also show in Table 1 that
these seven hybridomas differed from a theoretical
parental hybrid of 92 chromosomes (52 myeloma and 40
B-cell chromosomes) in gains of 13 to losses of 21 chro-
mosomes. These discrepancies between the experimental
and theoretical sums of chromosome numbers confirmed
original observations of Kohler and Milstein and subse-
quent studies by Wollweber et al. [23, 26].
In view of these results, we conclude that hybridomas
are generated by haphazard combinations of the chro-
mosomes of fused cells in single steps. This conclusion
explains the fast kinetics of hybridomagenesis, the ab-
sence of karyotypic intermediates, the low yields of only
a
b
Fig. 7 a, b Karyotype-arrays of five cells of hybridoma Hyb 94 (a) and hybridoma Hyb 1-5 (b). Both hybridomas are clonally heterogeneous with chromo-
somal clonalities ranging from 40 to 100%. For example, the individual chromosome numbers of the five hybridoma Hyb 94 cells analyzed range from
71 to 82 for a clonal average of 74 (Tables 1 and 3). Nevertheless, all five Hyb 94 karyotypes shared 28 of the 31 myeloma-specific marker chromosomes
and two Hyb 94-specific marker chromosomes (Table 3). The karyotype array of Hyb 1-5 was also relatively heterogeneous. Nevertheless, all five Hyb 1-5
karyotypes shared 30 of the 31 myeloma-specific marker chromosomes with the parental myeloma. In addition they shared all normal murine chromo-
somes with the parental mouse B-cell and some also with the parental myeloma. The simplest explanation for the high clonal heterogeneity of Hyb 94
and Hyb 105 suggests that these clones are still evolving precursor clones that are losing non-stabilizing chromosomes
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Table 2 Chromosome copy numbers of five kayotypes (K) of mouse myeloma Ag8 and hybridomas Hyb cl-12, Hyb CN-13 and Hyb cl-9
Clone Mouse Myeloma Hybridoma CN-13 Hybridoma cl-12 Hybridoma cl-9
Karyotypes K1 K2 K3 K4 K5 K1 K2 K3 K4 K5 K1 K2 K3 K4 K5 K1 K2 K3 K4 K5
Chromosome Copy # 53 53 51 51 49 84 88 87 84 84 101 90 75 89 87 113 115 111 90 95
Chromosomes
1 1 1 2 1 1 3 3 3 3 3 3 3 3 3 3 4 4 4 3 4
2 1 1 1 1 1 3 3 3 3 3 4 3 2 3 2 4 4 4 3 4
3 0 0 0 0 0 1 1 1 1 1 3 2 2 2 2 2 2 1 2 2
4 1 1 1 1 1 2 2 3 3 2 3 3 1 4 3 2 3 3 3 3
5 1 1 1 1 1 3 3 3 3 3 3 3 1 3 2 4 4 4 3 3
6 0 0 0 0 0 2 2 2 1 2 2 2 1 2 1 3 3 3 2 2
7 0 0 0 0 0 2 2 2 2 2 4 2 2 2 2 2 2 2 2 2
8 1 1 1 1 1 4 3 3 3 4 4 3 2 3 3 3 4 4 3 3
9 1 1 1 1 1 3 3 3 3 3 3 3 2 3 3 5 5 5 3 3
10 1 1 1 1 1 3 3 3 2 3 3 3 3 3 3 4 4 2 3 3
11 2 2 2 2 2 3 3 3 3 3 6 4 3 4 4 5 5 5 4 4
12 0 0 0 0 0 1 2 1 1 1 2 2 2 2 1 2 2 2 2 2
13 1 1 1 1 1 3 3 3 3 3 4 3 3 3 3 4 3 4 3 3
14 2 2 2 2 1 2 3 3 3 2 4 4 4 4 4 5 6 8 5 5
15 2 1 1 2 2 4 3 4 4 4 4 4 4 4 4 6 6 5 4 4
16 1 1 1 1 1 3 3 3 3 3 4 4 3 3 3 3 3 3 3 3
17 1 1 1 1 1 3 3 3 3 3 3 3 2 3 3 3 3 3 3 3
18 0 0 0 0 0 1 1 1 1 1 4 2 2 3 2 2 2 2 2 2
19 2 2 2 2 2 3 3 3 3 3 4 4 3 3 4 4 6 4 4 4
X 0 0 0 0 0 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2
Y 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
der(X;10) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 2 1 2
der(2;X) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1
der(X;18) 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1
der(19;X) 1 1 1 1 1 1 0 1 1 1 2 1 1 1 1 1 1 1 1 1
der(8;1) 1 1 1 1 0 0 1 1 1 0 1 1 1 1 1 0 0 0 1 1
der(13;1) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
der(2;3;1) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 2 1 1
der(1;3;7) 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 2 2 2 2 1
der(1;11) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 2 1 1
der(17;1) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
der(2;6) 1 1 1 1 1 0 1 0 1 0 1 1 1 1 1 1 1 1 0 0
der(2) 2 2 1 0 1 2 2 2 1 2 2 1 1 1 1 1 2 2 1 2
der(3;6) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 2 1 1
der(3;4) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 2 1 1
der(4;3) 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 1 1 1 1 1
der(4;5) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
der(5;4) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1
der(12;5) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
der(6;5) 1 1 1 1 1 0 1 1 1 0 1 1 1 1 1 1 1 0 0 1
der(17;6) 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1
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about one viable hybridoma per 10^4-5 fused cells
(Background), and the individuality of the resulting hy-
bridomas described here and previously (Background
and references [9, 11, 23, 26, 30]).
Are saltational single-step mechanisms also generating
spontaneous, late neoplastic progressions?
The following rare observations on the origin of spon-
taneous neoplastic progressions also support the salta-
tional theory of neoplastic progressions:
1) Distinguishing between paternal and maternal
chromosomes by restriction length polymorphisms
Onodera et al. found in 1992 highly symmetric
distributions of paternal and maternal chromosomes
in hyperdiploid leukemias. The authors concluded
that, “These results suggest that the hyperdiploid
karyotype usually arises by simultaneous gain of
chromosomes from a diploid karyotype during a single
abnormal cell division” [42]. This study was confirmed
and extended by Paulsson et al. in 2005 [43].
2) Studying progression of prostate cancers in 2013
Baca et al. detected “considerable genomic
derangement over relatively few events in prostate
cancer and other neoplasms, supporting a model of
punctuated cancer evolution.” [44].
3) Stepanenko et al. observed in 2015 that,
“Transfection of either the empty vector pcDNA3.1
or pcDNA3.1 CHI3L1 (a growth factor) into 293-
cells (a human embryo kidney cell line) initiated the
punctuated genome changes” of simultaneous gains
and losses of chromosomes [12].
4) Studying the progression of breast cancers Gao et al.
observed by whole genome sequencing in 2016,
“Despite profiling hundreds of single cells from
many spatial regions, we did not detect any
intermediate copy number profiles, indicative of
gradual evolution,” and concluded, “our data
challenge the paradigm of gradual evolution” [45].
5) In a comparison of single with multi-hit or “linear” the-
ories of metastatic progressions in 2016 Turajlic and
Swanton conclude, “It is conceivable that macroevolu-
tionary leaps (large-scale genomic alterations) could
catalyze all the steps to metastases, especially in narrow
time frames” [46] – much as those studied by us here.
Further we have shown previously that spontaneous
metastatic and drug-resistant progressions have individual
clonal karyotypes with numerous progression-specific
chomosomes [11, 34], just as the hybridomas studied here.
The individuality, complexity and clonality of the karyo-
types [9–11] and transcriptomes [10, 32] of spontneous
progressions indicate, however, a saltational, speciation-
type of event [9, 47, 48] – much like the saltational events
we found here for hybridomas.
It would appear then that saltational, single step
mechanisms could generate rare progressions “early”
and “late” by spontaneous karyotypic rearrangements
(see Background, Alternative single-step theory of pro-
gression), independent of cell fusions. Accordingly the
typically long latencies between cancers and progres-
sions would simply reflect the low probabilities of spe-
ciation by random karyotypic variations.
Nevertheless, there is also sporadic evidence for a role
of cell fusions in spontaneous progressions based on
Table 2 Chromosome copy numbers of five kayotypes (K) of mouse myeloma Ag8 and hybridomas Hyb cl-12, Hyb CN-13 and Hyb cl-9
(Continued)
Clone Mouse Myeloma Hybridoma CN-13 Hybridoma cl-12 Hybridoma cl-9
Karyotypes K1 K2 K3 K4 K5 K1 K2 K3 K4 K5 K1 K2 K3 K4 K5 K1 K2 K3 K4 K5
Chromosome Copy # 53 53 51 51 49 84 88 87 84 84 101 90 75 89 87 113 115 111 90 95
der(6;18;13) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
der(11;6) 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1
der(7) 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1
der(8;14) 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 0 0 0 0
der(9;14) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
der(12;10) 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1
der(12;17) 2 2 1 2 1 3 3 3 3 3 2 2 2 2 2 3 2 3 2 2
der(14;8;1;13) 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0
der(15) 2 2 2 2 2 2 4 2 2 2 2 2 2 2 2 3 3 3 2 3
der(16) 2 2 2 2 2 2 2 2 1 2 1 0 2 2 2 3 2 3 2 2
der(18;15) 1 1 1 1 1 1 1 1 1 1 0 1 1 0 1 1 1 1 1 1
Non-Clonal Markers 0 1 0 0 0 0 0 0 0 0 2 2 0 0 2 3 4 2 0 0
Bloomfield and Duesberg Molecular Cytogenetics  (2018) 11:4 Page 12 of 16
Table 3 Chromosome copy numbers of five karyotypes (K) of mouse hybridomas Hyb H12, Hyb F3, Hyb 94 and Hyb 1-5
Clone Hybridoma H12 Hybridoma F3 Hybridoma 94 Hybridoma 1-5
Karyotypes K1 K2 K3 K4 K5 K1 K2 K3 K4 K5 K1 K2 K3 K4 K5 K1 K2 K3 K4 K5
Chromosome Copy # 71 70 71 68 75 77 78 80 81 81 71 77 71 71 82 107 105 93 89 99
Chromosomes
1 2 2 2 1 2 3 3 3 3 3 1 1 1 2 1 2 3 2 3 2
2 2 2 2 2 2 3 3 3 3 3 3 4 3 4 3 3 3 4 3 4
3 0 0 0 0 0 1 1 0 1 1 0 0 0 1 1 0 1 1 0 1
4 2 2 2 2 2 2 2 2 2 2 1 2 1 1 2 2 2 2 1 2
5 2 2 2 2 2 2 2 1 2 2 1 1 2 0 2 4 3 3 2 3
6 1 1 1 1 1 2 2 3 2 2 2 2 2 2 2 2 1 2 2 2
7 1 2 2 1 2 1 2 2 2 2 2 3 3 3 3 1 4 2 2 2
8 1 1 1 1 2 3 3 2 3 3 3 3 2 1 2 3 3 1 2 2
9 2 2 2 2 2 3 3 3 3 3 2 3 2 2 3 5 3 2 1 4
10 1 1 1 1 1 3 3 3 2 3 2 2 3 3 3 2 2 1 2 1
11 3 3 3 3 3 4 4 3 5 4 3 1 1 3 3 6 3 4 4 4
12 0 0 0 0 0 0 0 0 0 0 0 0 2 1 1 1 2 2 2 2
13 3 3 3 2 4 1 1 1 2 1 2 1 2 1 2 2 1 3 1 3
14 2 2 2 2 2 2 2 3 2 3 3 4 2 3 3 4 5 4 5 4
15 3 3 3 3 3 4 4 4 4 4 4 2 2 5 4 4 4 4 4 3
16 2 2 2 2 3 2 3 3 3 3 3 2 2 2 3 2 3 3 4 1
17 1 1 1 1 1 3 3 3 3 3 2 3 2 2 2 1 2 2 1 2
18 2 2 2 2 2 2 2 2 2 2 0 1 1 1 2 2 1 1 1 1
19 2 2 2 2 3 3 3 3 3 3 3 3 3 3 3 2 3 2 3 3
X 1 1 1 1 1 2 2 2 2 2 2 2 0 2 2 2 2 1 1 3
Y 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
der(X;10) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 2 2 2 2
der(2;X) 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 1 1 2 2 1
der(X;18) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 1 1 1
der(19;X) 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 1 2
der(8;1) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 3 1 1 1
der(13;1) 1 1 1 1 0 1 1 1 1 1 2 2 1 1 1 1 1 1 0 1
der(2;3;1) 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 2 1 1 1 2
der(1;3;7) 1 1 1 1 1 1 1 1 1 1 2 1 1 0 1 1 2 2 1 2
der(1;11) 1 1 1 1 1 1 1 1 1 1 0 2 1 1 1 2 2 1 2 1
der(17;1) 1 1 1 1 0 1 1 1 0 1 1 0 0 1 1 2 2 2 0 2
der(2;6) 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 2 2 2 1 1
der(2) 2 2 2 2 0 1 2 1 1 1 2 2 2 3 0 4 0 1 2 2
der(3;6) 1 1 1 1 2 1 1 1 1 1 1 1 1 1 1 2 2 1 2 1
der(3;4) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2
der(4;3) 1 1 1 1 1 1 1 1 1 1 0 2 1 1 1 2 2 2 2 2
der(4;5) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0
der(5;4) 1 1 1 1 1 1 1 1 1 1 1 2 1 1 2 2 2 1 3 1
der(12;5) 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 2 1 1 1
der(6;5) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 1
der(17;6) 1 1 1 1 1 0 1 1 2 1 1 1 1 0 1 2 2 2 1 2
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several independent studies that were recently reviewed
by Lazebnick [49].
Finally, it did not escape our attention that the single-
step theory of progression or subspeciation of cancers
advanced here and previously [7, 10, 11, 33, 34, 48] de-
rives independent support from chromosomal theories
postulating that conventional speciations or subspecia-
tions also occur in single saltational steps - without
stable intermediates [47, 50–53].
Conclusions
We conclude that the evidence from the hybridoma
model tested here and the independent observations of
others including us about spontaneous clonal progres-
sions are based on saltational recombinations of cancer
chromosomes or of cancer chromosomes with chromo-
somes of heterologous cells. This model encourages the
following clinically relevant conclusions:
1) Our analysis of the karyotypic basis of progressions
here and previously [9–11] indicates that the
progressions of cancers are clonal and thus probably
the proximate causes of neoplastic progressions.
This conclusion confirms and extends a prior
prediction of Heng et al. [54].
2) The inherent karyotypic variability of cancer- and
progression-specific aneuploidy (Background) thus
explains and supports Foulds’ rule, that “progression
does not always reach an end-point within the life-
span of the host” [1], and Nowell’s similar
observation, “that the process is a continuing one”
[41]. Therefore, we conclude that progressions of
progressions are a lasting concern [1, 12], particu-
larly since progressions are responsible for 90% of
the mortality of cancers [55, 56].
3) Further we propose that the degree of cancer-
specific aneuploidy predicts the clinical risk of neo-
plastic progression, because cancer-specific aneu-
ploidy catalyzes karyotypic variation. This view thus




Thymidine-kinase deficient myeloma Ag8 cells and B-
cells from mice, induced to produce antibodies with
specific antigens, were fused at equal numbers for
about 5-10 min in about 50% polyethylene glycol
following established methods of Zeitler and Beatty
(UC Berkeley, above) and of the literature [26, 35, 36].
After fusions the cells were washed and incubated at
37 C for one to 2 days in selective medium containing
aminopterin, which inhibits natural thymidine synthe-
sis and thymidine, which substitutes lacking thymidine
after fusion with B-cells (Sigma Co, St Louis, MO or
ATCC, Rockville, MD). In these conditions fused Ag8
myeloma cells survive from added thymidine picked
up by B-cell-derived thymidine kinase. Within a few
days after fusion, un-fused myeloma cells die out due
to lack of thymidine and toxicity of aminopterin, and
Table 3 Chromosome copy numbers of five karyotypes (K) of mouse hybridomas Hyb H12, Hyb F3, Hyb 94 and Hyb 1-5 (Continued)
Clone Hybridoma H12 Hybridoma F3 Hybridoma 94 Hybridoma 1-5
Karyotypes K1 K2 K3 K4 K5 K1 K2 K3 K4 K5 K1 K2 K3 K4 K5 K1 K2 K3 K4 K5
Chromosome Copy # 71 70 71 68 75 77 78 80 81 81 71 77 71 71 82 107 105 93 89 99
der(6;18;13) 1 1 1 1 1 1 1 1 1 1 0 1 0 1 1 2 2 1 2 2
der(11;6) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2
der(7) 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 2 0 2 1 1
der(8;14) 1 0 1 1 1 1 1 1 1 1 0 1 0 1 1 1 0 0 1 1
der(9;14) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 2 2 1 2
der(12;10) 1 1 1 1 1 1 1 1 0 1 0 1 0 1 1 2 1 2 1 2
der(12;17) 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 3 3 3 4 3
der(14;8;1;13) 1 0 1 1 1 1 1 1 0 1 0 0 0 0 0 2 1 1 1 1
der(15) 2 2 2 2 2 1 1 1 1 1 2 1 2 1 1 4 4 2 4 3
der(16) 2 2 2 2 2 2 0 2 3 3 2 2 2 1 2 4 4 1 1 1
der(18;15) 2 2 2 2 2 1 1 1 1 1 1 1 1 1 2 2 2 1 2 1
der(X;1) 0 0 0 1 1
der(X;2;X;2?) 1 1 1 0 1
mar(11;6) 1 1 1 1 1
mar(1;11) 1 1 1 1 1
Non-Clonal Markers 1 1 1 0 2 0 0 3 2 0 1 1 6 0 4 0 1 3 0 3
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un-fused B-cells perish spontaneously within several
generations in culture. At that time normal medium
was used for the propagation of surviving hybridoma
cells. One to 2 weeks later microscopic clones ap-
peared, which were then sub-cultured in conventional
RPMI 1640 medium supplemented with 10% fetal calf
serum following published procedures [23, 26, 35, 36].
Clonal cultures of immortalized myeloma-B-cell hy-
brids arose from fusions at rates of about one hybrid-
oma per 10^4 to 5 myeloma cells. Hybridoma cells
were then propagated in suspension cultures in RPMI
1640 medium supplemented with 10% to 20% fetal calf
serum and 1% of 100× Antibiotic Antimycotic (Sigma
Co, St Louis, USA).
Karyotypic analyses myeloma and hybridoma cells
One to 2 days before karyotyping, cells were seeded at
about 50% confluence in a 5-cm culture dish with 3 ml of
the medium described above. After reaching ~75% quasi-
confluence, 250–300 ng colcemid in 25–30 μl solution
(KaryoMax, Gibco) was added to 3 ml medium. The cul-
ture was then incubated at 37 °C for 4–8 h. Subsequently
cells were washed twice with 3 ml of physiological saline
and then incubated in 0.075 M KCl at 37 °C for 15 min.
The cell suspension was then cooled in ice-water, mixed
(‘prefixed’) with 0.1 volume of the freshly mixed glacial
acetic acid-methanol (1:3, vol. per vol.) and centrifuged at
800 g for 6 min at room temperature. The cell pellet was
then suspended in about 100 μl supernatant and mixed
drop-wise with 5 ml of the ice-cold acetic acid-methanol
solution and then incubated at room temperature for
15–30 min or overnight at 5C. This cell suspension was
then pelleted and was then either once more re-
suspended in fixative and pelleted, or was directly re-
suspended in a small volume of the acetic acid-methanol
solution for microscopic examination. For this purpose an
aliquot of a visually turbid suspension was transferred
with a micropipette tip to a glass microscope slide,
allowed to evaporate at room temperature and inspected
under the microscope at 200× for an adequate, non-
overlapping density of metaphase chromosomes. Meta-
phase chromosomes attached to glass slides were then hy-
bridized to color-coded, mouse chromosome-specific
DNA probes as described by the manufacturer, MetaSys-
tems (Newton, MA 02458). Chromosomes were then
sorted into conventional karyotypes with a computerized
Zeiss Imager M1 microscope, programmed by MetaSys-
tems (Newton, MA 02458) following published procedures
[11, 33, 34, 61].
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